Hypo- and Hyper-Assembly Diseases of RNA–Protein Complexes

Trends in Molecular Medicine

Volumn 22, Issue 7, 2016, Pages 615-628

  Shukla, Siddharth ^a   Parker, Roy ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

dyskeratosis congenita; RNA quality control; RNP assembly; spinal muscular atrophy; stress granules; therapy

Indexed keywords

RIBONUCLEOPROTEIN; RNA; SMALL NUCLEAR RNA; TELOMERASE; UNTRANSLATED RNA;

DYSKERATOSIS CONGENITA; GENETIC DISORDER; HUMAN; NONHUMAN; PATHOLOGY; PROTEIN ASSEMBLY; REVIEW; RNA DEGRADATION; RNP HYPER ASSEMBLY DISEASE; RNP HYPO ASSEMBLY DISEASE; SPINAL MUSCULAR ATROPHY; ABNORMALITIES; ANIMAL; DWARFISM; GENETICS; HAIR; HIRSCHSPRUNG DISEASE; IMMUNE DEFICIENCY; INTRAUTERINE GROWTH RETARDATION; MALLORY BODY; METABOLISM; MICROCEPHALY; MUSCULAR DYSTROPHY; MUTATION; OSTEOCHONDRODYSPLASIAS; PARKINSON DISEASE; RNA STABILITY; SCOLIOSIS; WALKER WARBURG SYNDROME;

ANIMALS; DWARFISM; DYSKERATOSIS CONGENITA; FETAL GROWTH RETARDATION; HAIR; HIRSCHSPRUNG DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALLORY BODIES; MICROCEPHALY; MUSCULAR ATROPHY, SPINAL; MUSCULAR DYSTROPHIES; MUTATION; OSTEOCHONDRODYSPLASIAS; PARKINSON DISEASE; RIBONUCLEOPROTEINS; RNA STABILITY; SCOLIOSIS; WALKER-WARBURG SYNDROME;

EID: 84971607230     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.05.005     Document Type: Review

References (119)

1. 1 Singh, G., et al. The clothes make the mRNA: past and present trends in mRNP fashion. Annu. Rev. Biochem. 84 (2015), 325–354.
2. 2 Müller-McNicoll, M., Neugebauer, K.M., How cells get the message: dynamic assembly and function of mRNA–protein complexes. Nat. Rev. Genet. 14 (2013), 275–287.
3. 3 Mitrea, D.M., Kriwacki, R.W., Phase separation in biology; functional organization of a higher order. Cell Commun. Signal, 14, 2016, 1.
4. 4 Renton, A.E., et al. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17 (2014), 17–23.
5. 5 Kim, H.J., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495 (2013), 467–473.
6. 6 Meola, G., Cardani, R., Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. BBA Mol. Basis Dis. 1852 (2015), 594–606.
7. 7 Armanios, M., Blackburn, E.H., The telomere syndromes. Nat. Rev. Genet. 13 (2012), 693–704.
8. 8 Mason, P.J., Bessler, M., The genetics of dyskeratosis congenita. Cancer Genet. 204 (2011), 635–645.
9. 9 Wong, J.M.Y., Collins, K., Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 20 (2006), 2848–2858.
10. 10 Moon, D.H., et al. Poly(A)-specific ribonuclease (PARN) mediates 3′-end maturation of the telomerase RNA component. Nat. Genet. 47 (2015), 1482–1488.
11. 11 Shukla, S., et al. Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects. Nat. Struct. Mol. Biol. 23 (2016), 286–292.
12. 12 Tseng, C-K., et al. Human telomerase RNA processing and quality control. Cell Rep. 13 (2015), 2232–2243.
13. 13 Nguyen, D., et al. A polyadenylation-dependent 3′ end maturation pathway is required for the synthesis of the human telomerase RNA. Cell Rep. 13 (2015), 2244–2257.
14. 14 Dhanraj, S., et al. Bone marrow failure and developmental delay caused by mutations in poly(A)-specific ribonuclease (PARN). J. Med. Genet. 52 (2015), 738–748.
15. 15 Tummala, H., et al. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J. Clin. Invest. 125 (2015), 2151–2160.
16. 16 Stuart, B.D., et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat. Genet. 47 (2015), 512–517.
17. 17 Lefebvre, S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995), 155–165.
18. 18 Pellizzoni, L., et al. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 95 (1998), 615–624.
19. 19 Lorson, C.L., et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 6307–6311.
20. 20 Cho, S., Dreyfuss, G., A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. 24 (2010), 438–442.
21. 21 Zhang, Z., et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133 (2008), 585–600.
22. 22 Gabanella, F., et al. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE, 2, 2007, e921.
23. 23 Lotti, F., et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151 (2012), 440–454.
24. 24 Shukla, S., Parker, R., Quality control of assembly-defective U1 snRNAs by decapping and 5′-to-3′ exonucleolytic digestion. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E3277–E3286.
25. 25 Winkler, C., Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev. 19 (2005), 2320–2330.
26. 26 Fischer, U., et al. Biogenesis of spliceosomal small nuclear ribonucleoproteins. WIREs RNA 2 (2011), 718–731.
27. 27 Tsalikis, J., et al. Intracellular bacterial pathogens trigger the formation of U small nuclear RNA bodies (U bodies) through metabolic stress induction. J. Biol. Chem. 290 (2015), 20904–20918.
28. 28 Lindahl, L., et al. RNase MRP is required for entry of 35S precursor rRNA into the canonical processing pathway. RNA 15 (2009), 1407–1416.
29. 29 Chu, S., et al. The RNA of RNase MRP is required for normal processing of ribosomal RNA. Proc. Natl. Acad. Sci. U.S.A. 91 (1994), 659–663.
30. 30 Lygerou, Z., et al. Accurate processing of a eukaryotic precursor ribosomal RNA by ribonuclease MRP in vitro. Science 272 (1996), 268–270.
31. 31 Ridanpää, M., et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104 (2001), 195–203.
32. 32 Hermanns, P., et al. Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. Hum. Mol. Genet. 14 (2005), 3723–3740.
33. 33 Nakashima, E., et al. Cartilage hair hypoplasia mutations that lead toRMRP promoter inefficiency or RNA transcript instability. Am. J. Med. Genet. 143 (2007), 2675–2681.
34. 34 Huang, W., et al. DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature 528 (2015), 517–522.
35. 35 He, H., et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science 332 (2011), 238–240.
36. 36 Edery, P., et al. Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science 332 (2011), 240–243.
37. 37 Jafarifar, F., et al. Biochemical defects in minor spliceosome function in the developmental disorder MOPD I. RNA 20 (2014), 1078–1089.
38. 38 Waggoner, S.A., Liebhaber, S.A., Regulation of alpha-globin mRNA stability. Exp. Biol. Med. (Maywood) 228 (2003), 387–395.
39. 39 Weiss, I.M., Liebhaber, S.A., Erythroid cell-specific mRNA stability elements in the alpha 2-globin 3′ nontranslated region. Mol. Cell. Biol. 15 (1995), 2457–2465.
40. 40 Allamand, V., et al. A single homozygous point mutation in a 3′untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy. EMBO Rep. 4 (2006), 450–454.
41. 41 Kobayashi, K., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394 (1998), 388–392.
42. 42 Cardo, L.F., et al. The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease. J. Hum. Genet. 59 (2014), 346–348.
43. 43 Buchan, J.R., Parker, R., Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 36 (2009), 932–941.
44. 44 Krichevsky, A.M., Kosik, K.S., Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 32 (2001), 683–696.
45. 45 Sengupta, M.S., Boag, P.R., Germ granules and the control of mRNA translation. IUBMB Life 64 (2012), 586–594.
46. 46 Li, Y.R., et al. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201 (2013), 361–372.
47. 47 Alberti, S., et al. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137 (2009), 146–158.
48. 48 Guo, W., et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat. Struct. Mol. Biol. 18 (2011), 822–830.
49. 49 Igaz, L.M., et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J. Clin. Invest. 121 (2011), 726–738.
50. 50 Barmada, S.J., et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30 (2010), 639–649.
51. 51 Elden, A.C., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466 (2010), 1069–1075.
52. 52 Imbert, G., et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat. Genet. 14 (1996), 285–291.
53. 53 Simón-Sánchez, J., et al. Analysis of SCA-2 and SCA-3 repeats in parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. Neurosci. Lett. 382 (2005), 191–194.
54. 54 McCann, C., et al. The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), E655–E662.
55. 55 Nonhoff, U., et al. Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell 18 (2007), 1385–1396.
56. 56 Buchan, J.R., et al. P bodies promote stress granule assembly in Saccharomyces cerevisiae. J. Cell Biol. 183 (2008), 441–455.
57. 57 Shelkovnikova, T.A., et al. Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum. Mol. Genet. 23 (2014), 5211–5226.
58. 58 Johnson, J.O., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68 (2010), 857–864.
59. 59 Buchan, J.R., et al. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell 153 (2013), 1461–1474.
60. 60 Couthouis, J., et al. Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy. Neuromuscul. Disord. 24 (2014), 431–435.
61. 61 Bengoechea, R., et al. Myofibrillar disruption and RNA-binding protein aggregation in a mouse model of limb-girdle muscular dystrophy 1D. Hum. Mol. Genet. 24 (2015), 6588–6602.
62. 62 Li, S., et al. Genetic interaction of hnRNPA2B1 and DNAJB6 in a Drosophila model of multisystem proteinopathy. Hum. Mol. Genet. 25 (2016), 936–950.
63. 63 Walters, R.W., et al. Differential effects of Ydj1 and Sis1 on Hsp70-mediated clearance of stress granules in Saccharomyces cerevisiae. RNA 21 (2015), 1660–1671.
64. 64 Jones, D.T.W., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488 (2012), 100–105.
65. 65 Pugh, T.J., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488 (2012), 106–110.
66. 66 Robinson, G., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488 (2012), 43–48.
67. 67 Epling, L.B., et al. Cancer-associated mutants of RNA helicase DDX3X are defective in RNA-stimulated ATP hydrolysis. J. Mol. Biol. 427 (2015), 1779–1796.
68. 68 Hilliker, A., et al. The DEAD-box protein Ded1 modulates translation by the formation and resolution of an eIF4F–mRNA complex. Mol. Cell 43 (2011), 962–972.
69. 69 Arnold, E.S., et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), E736–E745.
70. 70 Arimoto, K., et al. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat. Cell Biol. 10 (2008), 1324–1332.
71. 71 Liquori, C.L., et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293 (2001), 864–867.
72. 72 Mahadevan, M., et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255 (1992), 1253–1255.
73. 73 Brook, J.D., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell, 69, 1992, 385.
74. 74 Fu, Y.H., et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255 (1992), 1256–1258.
75. 75 Timchenko, L.T., et al. Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 24 (1996), 4407–4414.
76. 76 Philips, A.V., et al. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280 (1998), 737–741.
77. 77 Miller, J.W., et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19 (2000), 4439–4448.
78. 78 Kanadia, R.N., et al. A muscleblind knockout model for myotonic dystrophy. Science 302 (2003), 1978–1980.
79. 79 Jiang, H., et al. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13 (2004), 3079–3088.
80. 80 Kuyumcu-Martinez, N.M., et al. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 28 (2007), 68–78.
81. 81 DeJesus-Hernandez, M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72 (2011), 245–256.
82. 82 Renton, A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72 (2011), 257–268.
83. 83 Mizielinska, S., et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126 (2013), 845–857.
84. 84 Zu, T., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), E4968–E4977.
85. 85 Cooper-Knock, J., et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 137 (2014), 2040–2051.
86. 86 Haeusler, A.R., et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507 (2014), 195–200.
87. 87 Mizielinska, S., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345 (2014), 1192–1194.
88. 88 Ash, P.E.A., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77 (2013), 639–646.
89. 89 Farg, M.A., et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 23 (2014), 3579–3595.
90. 90 Kwon, I., et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345 (2014), 1139–1145.
91. 91 O'Rourke, J.G., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351 (2016), 1324–1329.
92. 92 Zhang, Y-J., et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19 (2016), 668–677.
93. 93 Chew, J., et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348 (2015), 1151–1154.
94. 94 Freibaum, B.D., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525 (2015), 129–133.
95. 95 Zhang, K., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525 (2015), 56–61.
96. 96 Jovičić, A., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18 (2015), 1226–1229.
97. 97 Koob, M.D., et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat. Genet. 21 (1999), 379–384.
98. 98 Day, J.W., et al. Spinocerebellar ataxia type 8: clinical features in a large family. Neurology 55 (2000), 649–657.
99. 99 Moseley, M.L., et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38 (2006), 758–769.
100. 100 Daughters, R.S., et al. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet., 5, 2009, e1000600.
101. 101 Zu, T., et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 260–265.
102. 102 Houseley, J., Tollervey, D., The many pathways of RNA degradation. Cell 136 (2009), 763–776.
103. 103 Song, M.-G., et al. Multiple mRNA decapping enzymes in mammalian cells. Mol. Cell 40 (2010), 423–432.
104. 104 Song, M.G., et al. Multiple Nudix family proteins possess mRNA decapping activity. RNA 19 (2013), 390–399.
105. 105 Jiao, X., et al. A mammalian pre-mRNA 5′ end capping quality control mechanism and an unexpected link of capping to pre-mRNA processing. Mol. Cell 50 (2013), 104–115.
106. 106 Li, Y., et al. Differential utilization of decapping enzymes in mammalian mRNA decay pathways. RNA 17 (2011), 419–428.
107. 107 Miller, T.M., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12 (2013), 435–442.
108. 108 Wheeler, T.M., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488 (2012), 111–115.
109. 109 Hu, J., et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27 (2009), 478–484.
110. 110 Wheeler, T.M., et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325 (2009), 336–339.
111. 111 Lagier-Tourenne, C., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), E4530–E4539.
112. 112 Staats, K.A., et al. Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol. Neurodegener., 8, 2013, 31.
113. 113 Zhang, X., et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy 7 (2011), 412–425.
114. 114 Childs-Disney, J.L., et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat. Commun., 4, 2013, 2044.
115. 115 Rzuczek, S.G., et al. A toxic RNA catalyzes the in cellulo synthesis of its own inhibitor. Angew. Chem. Int. Ed. Engl. 53 (2014), 10956–10959.
116. 116 Childs-Disney, J.L., et al. Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity. ACS Chem. Biol. 9 (2014), 538–550.
117. 117 Mitchell, J.R., et al. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402 (1999), 551–555.
118. 118 Vulliamy, T., et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413 (2001), 432–435.
119. 119 Moghadaszadeh, B., et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat. Genet. 29 (2001), 17–18.